

Patient name: example report

HN: 123456789

Patient name: example report

HN: 123456789

Date of birth: 02/01/1985

Sex: Male

Sample type: EDTA Blood

Specimen id: 12345678-1

Date of collection: 01/03/2022

Date of receive: 01/03/2022

Date of result: 28/04/2023

Physician order: Dr. Examplereport Test

TEST INFORMATION

This test is a screening tool to determine the risks of Early childhood asthma, wheezing and adult-onset of asthma and COPD by analyzing 1 SNP marker (rs6967330).

VARIANTS RELEVANT TO INDICATION FOR TESTING

Gene	Chromosome position	rsID	Variant	Interpretation
CDHR3	7:105658451	rs6967330	Homozygous G/G	No evidence of increased risk

References

- Bønnelykke K, et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. *Nat Genet.* 2014 Jan;46(1):51-5.
- Basnet S, et al. CDHR3 Asthma-Risk Genotype Affects Susceptibility of Airway Epithelium to Rhinovirus C Infections. *Am J Respir Cell Mol Biol.* 2019 Oct;61(4):450-458.
- Everman JL. Functional genomics of CDHR3 confirms its role in HRV-C infection and childhood asthma exacerbations. *J Allergy Clin Immunol.* 2019 Oct;144(4):962-971.
- Leung TF, et al. Cadherin-related family member 3 gene impacts childhood asthma in Chinese children. *Pediatr Allergy Immunol.* 2020 Feb;31(2):133-142.
- Shigemasa R, et al. Genetic impact of CDHR3 on the adult onset of asthma and COPD. *Clin Exp Allergy.* 2020 Nov;50(11):1223-1229.

Patient name: example report

HN: 123456789

METHODOLOGY

Genomic DNA is extracted from an individual at Bumrungrad Hospital. DNA sample is sent to the Macrogen, Korea to process Whole Genome Sequencing (WGS). Library preparation, clustering and sequencing are processed on the Illumina platform. Data in a mean depth of 30X were generated. Reads from the sequence output were aligned to the human reference genome (GRCh37) and processed for variant calling (SNP/Indel) using the Illumina pipeline (Isaac.v4). Manta is performed to identify structural variants and large indels while copy number variant is identified by Control-FREEC. The tertiary analysis is performed at Bumrungrad Hospital. The variants were annotated and filtered using the Golden Helix VarSeq analysis workflow implementing the ACMG guidelines for the interpretation of sequence variants. This includes a comparison against the gnomAD population catalog of variants in 123,136 exomes, the 1000 Genomes Project Consortium's publication of 2,500 genomes, the NCBI ClinVar database of clinical assertions on variant's pathogenicity and multiple lines of computational evidence on conservation and functional impact.

VARIANT ASSESSMENT PROCESS

The following databases and in-silico algorithms are used to annotate and evaluate the impact of the variant in the context of human disease: 1000 genomes, gnomAD, ClinVar, OMIM, dbSNP, NCIB RefSeq Genes, ExAC Gene Constraints, VS-SIFT, VS-PolyPhen2, PhyloP, GERP++, GeneSplicer, MaxEntScan, NNSplice, PWM Splice Predictor. Analysis was reported using the to HGVS nomenclature (www.hgvs.org/mutnomen) as implemented by the VarSeq transcript annotation algorithm. The reported transcript matches that used most frequently by the clinical labs submitting to ClinVar.

LIMITATIONS

It should be noted that the interpretation of this test is based on a limited number of SNP and might not cover all possible variants related to the particular condition. Lifestyle and other factors that might affect the condition are not accounted on the analysis.

DISCLAIMER

The results of this test are not intended, and should not be used to diagnose or treat any disease or medical condition, but could provide useful information about how to manage any disease or conditions you may have holistically. There is also a possibility of an error in the result due to contaminants in the sample, rare technical errors, and a rare genetic variant that could interfere with the analysis. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.